Acquisition expands Axol’s iPSC-derived cell models and service offering to include ophthalmology and dermatology CAMBRIDGE / EDINBURGH, UK, and GRASSE, FRANCE, October 2024: Axol Bioscience Ltd. (Axol), a leading induced pluripotent stem cell (iPSC) technology provider for drug discovery, today announced it has fully acquired Phenocell SAS, a pioneer in iPSC-based products and bioassays for skin and retinal disorders. The acquisition extends Axol’s portfolio of iPSC-derived cell … Continue reading Axol Bioscience acquires Phenocell to advance human disease models